CN1281436A - 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 - Google Patents
用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 Download PDFInfo
- Publication number
- CN1281436A CN1281436A CN98811895A CN98811895A CN1281436A CN 1281436 A CN1281436 A CN 1281436A CN 98811895 A CN98811895 A CN 98811895A CN 98811895 A CN98811895 A CN 98811895A CN 1281436 A CN1281436 A CN 1281436A
- Authority
- CN
- China
- Prior art keywords
- low
- carbon
- carbon alkyl
- amino
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
举例化合物 | 环氧化酶Ⅰ%抑制(100微摩尔) |
(*-1000-M) | |
舒林酸硫化物 | 86 |
1 | <25 |
细胞形态 | DNA片断化 | |||
化合物 | %程序性死亡细胞(1微摩尔) | 刺激倍数(100微摩尔) | 有效半数剂量(微摩尔) | |
1 | 88 | 4.2 | 29 | |
2 | 5.4 | |||
3 | 8.5 | |||
4 | 3.9 | |||
38 | 15 |
Claims (79)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/989,353 | 1997-12-12 | ||
US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
US09/206,245 | 1998-12-07 | ||
US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1281436A true CN1281436A (zh) | 2001-01-24 |
CN100436418C CN100436418C (zh) | 2008-11-26 |
Family
ID=26901185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988118955A Expired - Fee Related CN100436418C (zh) | 1997-12-12 | 1998-12-11 | 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 |
Country Status (18)
Country | Link |
---|---|
US (3) | US6166053A (zh) |
EP (1) | EP1044187B1 (zh) |
JP (1) | JP4307719B2 (zh) |
CN (1) | CN100436418C (zh) |
AT (1) | ATE257152T1 (zh) |
AU (1) | AU752072B2 (zh) |
BR (1) | BR9813540A (zh) |
CA (1) | CA2314339C (zh) |
CZ (1) | CZ298826B6 (zh) |
DE (1) | DE69820908T2 (zh) |
ES (1) | ES2212383T3 (zh) |
HU (1) | HU227153B1 (zh) |
IL (1) | IL136603A0 (zh) |
NO (1) | NO317097B1 (zh) |
NZ (1) | NZ504958A (zh) |
PL (1) | PL196936B1 (zh) |
TR (1) | TR200001687T2 (zh) |
WO (1) | WO1999031065A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
US10566838B2 (en) | 2009-08-07 | 2020-02-18 | Auckland Uniservices Limited | Inductive power transfer system |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200001687T2 (tr) * | 1997-12-12 | 2000-10-23 | Cell Pathways, Inc. | Neopleasyo için N-benzil-3-indenilasetamid türevleri. |
IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
EP1278522B1 (en) * | 2000-04-19 | 2006-10-25 | Lilly Icos LLC | Pde-v inhibitors for treatment of parkinson's disease |
DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
CA2568906C (en) | 2004-06-02 | 2010-09-21 | Merit Diamond Corporation | Comfort interior for jewelry and jewelry including that interior |
NZ569430A (en) * | 2006-01-04 | 2012-05-25 | Southern Res Inst | Derivatives of sulindac, use thereof and preparation thereof |
WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
WO2010053910A1 (en) * | 2008-11-04 | 2010-05-14 | Wellstat Therapeutics Corporation | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids |
US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
EP3784228A1 (en) | 2018-04-26 | 2021-03-03 | ADT Pharmaceuticals, LLC | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0508586B1 (en) * | 1991-03-08 | 1995-05-31 | Fgn, Inc. | Substituted indenyl compounds |
US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
TR200001687T2 (tr) * | 1997-12-12 | 2000-10-23 | Cell Pathways, Inc. | Neopleasyo için N-benzil-3-indenilasetamid türevleri. |
US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
-
1998
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 EP EP98959050A patent/EP1044187B1/en not_active Expired - Lifetime
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en active IP Right Grant
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
US10566838B2 (en) | 2009-08-07 | 2020-02-18 | Auckland Uniservices Limited | Inductive power transfer system |
Also Published As
Publication number | Publication date |
---|---|
HUP0100170A1 (hu) | 2001-07-30 |
DE69820908D1 (de) | 2004-02-05 |
CZ20002157A3 (cs) | 2000-10-11 |
JP2002508358A (ja) | 2002-03-19 |
BR9813540A (pt) | 2000-10-10 |
NO20002972L (no) | 2000-08-09 |
JP4307719B2 (ja) | 2009-08-05 |
AU752072B2 (en) | 2002-09-05 |
HUP0100170A3 (en) | 2001-12-28 |
EP1044187A1 (en) | 2000-10-18 |
PL341151A1 (en) | 2001-03-26 |
HU227153B1 (en) | 2010-08-30 |
CA2314339A1 (en) | 1999-06-24 |
AU1498199A (en) | 1999-07-05 |
ES2212383T3 (es) | 2004-07-16 |
NO317097B1 (no) | 2004-08-09 |
DE69820908T2 (de) | 2004-12-23 |
US20030009033A1 (en) | 2003-01-09 |
US6426349B1 (en) | 2002-07-30 |
IL136603A0 (en) | 2001-06-14 |
NO20002972D0 (no) | 2000-06-09 |
NZ504958A (en) | 2003-03-28 |
CA2314339C (en) | 2009-09-08 |
WO1999031065A1 (en) | 1999-06-24 |
PL196936B1 (pl) | 2008-02-29 |
CN100436418C (zh) | 2008-11-26 |
CZ298826B6 (cs) | 2008-02-20 |
TR200001687T2 (tr) | 2000-10-23 |
EP1044187B1 (en) | 2004-01-02 |
US6610854B2 (en) | 2003-08-26 |
US6166053A (en) | 2000-12-26 |
ATE257152T1 (de) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1281436A (zh) | 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 | |
CN1216867C (zh) | 2-氨基-烟酰胺衍生物及其作为vegf-受体酪氨酸激酶抑制剂的用途 | |
CN1177830C (zh) | 苯并杂环和它们作为mek抑制剂的用途 | |
CN1152863C (zh) | 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物 | |
CN1211382C (zh) | 喹唑啉二甲苯磺酸盐化合物 | |
CN1152031C (zh) | 具有血管生成抑制活性的异喹啉衍生物 | |
CN1085666C (zh) | 用于抑制蛋白质酪氨酸激酶介导的细胞增殖的6-芳基吡啶并[2,3-d]嘧啶和1,5-二氮杂萘 | |
CN1152014C (zh) | N-芳基邻氨基苯甲酸衍生物及其用途 | |
CN1282640C (zh) | N-芳基苯乙酰胺衍生物及包含所述化合物的药物组合物 | |
CN1231458C (zh) | 新的芳氧基-烷基-二烷基胺类化合物 | |
CN1956966A (zh) | 喹唑啉衍生物及其治疗用途 | |
CN1894215A (zh) | 治疗细胞增殖疾病的化合物 | |
CN1373662A (zh) | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 | |
CN1705635A (zh) | 组蛋白脱乙酰酶抑制剂 | |
CN1867331A (zh) | 作为TNF-α调节剂的沙利度胺类似物 | |
CN1214339A (zh) | 吡唑衍生物、其制备方法和在药物中的应用 | |
CN1914152A (zh) | 新化合物及其制备方法和用途 | |
CN1582277A (zh) | 用作糖原合酶激酶3β抑制剂的酰胺衍生物 | |
CN1259950A (zh) | 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途 | |
CN1320037A (zh) | 抗病毒的吲哚氧代乙酰基哌嗪衍生物 | |
CN1211239A (zh) | 作为vegf抑制剂的喹唑啉衍生物 | |
CN1514824A (zh) | 用作抗肿瘤剂的苯甲酰基磺酰胺类化合物和磺酰基苄脒类化合物 | |
CN1387517A (zh) | 作为环加氧酶-2抑制剂的5-芳基-1h-1,2,4-三唑化合物及含有它们的药物组合物 | |
CN1433312A (zh) | 作为治疗剂的巴比妥酸类似物 | |
CN1040980C (zh) | 第二信使细胞信号传送抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: OSI PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: CELL PATHWAYS, INC. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040611 Address after: American Pennsylvania Applicant after: Osi Pharm Inc. Co-applicant after: The University of Arizona Address before: American Pennsylvania Applicant before: Cell Pathways, Inc. Co-applicant before: The University of Arizona |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1030947 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081126 Termination date: 20121211 |